Male (%) | 7 (100) |
Age (years) | 62.1 ± 13.3 |
Dry weight (kg) | 69.6 ± 17.8 |
Duration of diabetes (years)* | 19 (12–40) |
HD duration (months)* | 1 (0.5–30) |
Glucose level of dialysate, 125/150Â mg/dL | 5/2 |
Red blood cell (/μL) | 355.3 ± 72.3 |
Hemoglobin concentration (g/dL) | 10.3 ± 1.8 |
Hematocrit (%) | 32.6 ± 4.9 |
Albumin concentration (g/dL) | 3.8 ± 1.0 |
HbA1c (%) | 6.8 ± 2.1 |
Glycated albumin (%) | 24.7 ± 10.2 |
Fasting glucose level (mg/dL) | 123.6 ± 80.4 |
Fasting C-peptide (ng/mL)* | 3.70 (0.14–10.80) |
Dietary treatment (kcal/IBWkg) | 30.9 ± 2.4 |
ESA dosage (U/week)* | 8000 (0–12,000) |
Diabetic treatment, N | Â |
  Insulin + OHA/Insulin + GLP-1A/OHA alone | 4/1/2 |
Diabetic neuropathy, −/ +  | 0/7 |
Diabetic retinopathy, None/SDR/pre-PDR/PDR | 2/0/0/5 |